膀胱尿路上皮癌分子亚型:2411例肿瘤的荟萃队列分析
该研究整合公共基因表达数据,构建了包含2411例非肌层浸润性和肌层浸润性膀胱癌的荟萃队列,识别出六种分子亚型,其总生存期和分子特征各异。约20%的非肌层浸润性膀胱癌表现出肌层浸润性亚型特征且5年总生存率较低(81% vs 96%)。研究提示分子亚型有助于指导治疗选择。
要点
- 识别出六种分子亚型:Neural-like、HER2-like、Papillary-like、Luminal-like、MES和SCC。
- SCC亚型中位总生存期最短(20.6个月),Papillary-like最长(>135个月)。
- 约20%非肌层浸润性膀胱癌具有肌层浸润性亚型特征且预后较差。
核心结论
- 膀胱癌可分层为六种分子亚型,各亚型总生存期和分子特征不同。
- 高风险进展的非肌层浸润性膀胱癌可显示肌层浸润性膀胱癌的分子特征。
研究设计与样本
- 整合公开可用的基因表达数据并重新分析,数据集包含2411例独特肿瘤,涵盖非肌层浸润性和肌层浸润性膀胱癌。
- 亚型在The Cancer Genome Atlas、UROMOL和IMvigor210中重现。
主要发现
- Neural-like亚型中位总生存期87个月,多见于肌层浸润性膀胱癌,WNT/β-catenin信号高。
- HER2-like亚型中位总生存期107.7个月,在非肌层浸润性和肌层浸润性膀胱癌中均匀分布,ERBB2扩增和信号较高。
- Papillary-like亚型中位总生存期>135个月,为非肌层浸润性亚型,富集尿路上皮分化基因,FGFR3突变、扩增和FGFR3-TACC3融合频率高。
- Luminal-like亚型中位总生存期91.7个月,主要为非肌层浸润性,MAPK信号较高,KRAS和KMT2C/D突变较多。
- MES和SCC亚型中位总生存期分别为86.6个月和20.6个月,多见于肌层浸润性膀胱癌;MES中AXL信号高,SCC中PD1、CTLA4信号和M2巨噬细胞浸润升高。
关键数值与推荐
- 六种分子亚型的中位总生存期:Neural-like 87个月,HER2-like 107.7个月,Papillary-like >135个月,Luminal-like 91.7个月,MES 86.6个月,SCC 20.6个月。
- 约20%的非肌层浸润性膀胱癌显示肌层浸润性亚型特征,其5年总生存率为81%,而Papillary-like非肌层浸润性膀胱癌为96%。
临床怎么用
- 分子亚型可用于识别高风险进展的非肌层浸润性膀胱癌,辅助治疗选择。
- Papillary-like亚型中FGFR3突变、扩增和融合频率高,可能指导靶向治疗。
- SCC亚型中PD1、CTLA4信号和M2巨噬细胞浸润升高,可能提示免疫治疗机会。
局限性
- 临床注释不完整。
- 由于跨基因表达定量技术比较,分析基于转录组子集。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previous molecular subtyping for bladder carcinoma (BLCA) involved <450 samples, with diverse classifications. OBJECTIVE: To identify molecular subtypes by curating a large BLCA dataset. DESIGN, SETTING, AND PARTICIPANTS: Gene expression publicly available were combined and reanalyzed. The dataset contained 2411 unique tumors encompassing non-muscle-invasive (NMIBC) and muscle-invasive BLCA (MIBC). Subtypes were reproduced on The Cancer Genome Atlas, UROMOL, and IMvigor210. INTERVENTION: Subtypes were assigned by gene expression. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Kaplan-Meier analyses were performed for subtype-clinical outcome correlations; Chi-square/Fisher exact tests were used for subtype-clinicopathological parameters associations. RESULTS AND LIMITATIONS: We identified six molecular subtypes with different overall survival (OS) and molecular features. Subtype Neural-like (median OS, 87 mo) is prevalent in MIBC and characterized by high WNT/β-catenin signaling. HER2-like (107.7 mo) is distributed evenly across NMIBC and MIBC, with higher ERBB2 amplification and signaling. Papillary-like (>135 mo), an NMIBC subtype enriched in urothelial differentiation genes, shows a high frequency of actionable FGFR3 mutations, amplifications, and FGFR3-TACC3 fusion. Luminal-like (91.7 mo), predominantly NMIBC, has higher MAPK signaling and more KRAS and KMT2C/D mutations than other subtypes. Mesenchymal-like (MES; 86.6 mo) and Squamous-cell carcinoma-like (SCC; 20.6 mo) are predominant in MIBC. MES is high in AXL signaling, whereas SCC has elevated PD1, CTLA4 signaling, and macrophage M2 infiltration. About 20% of NMIBCs show MIBC subtype traits and a lower 5-yr OS rate than Papillary-like NMIBC (81% vs 96%). The main limitations of our study are the incomplete clinical annotation, and the analyses were based on transcriptome subset due to comparisons across gene expression quantification technologies. CONCLUSIONS: BLCA can be stratified into six molecular subtypes. NMIBC, with a high risk of progression, displays the molecular features of MIBC. PATIENT SUMMARY: Biomarkers are urgently needed to guide patient treatment selection and avoid unnecessary toxicities in those who fail to respond. We believe molecular subtyping is a promising way to tailor disease management for those who will benefit most.
引用
- Tan TZ, Rouanne M, Tan KT, et al. Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors. Eur Urol. 2018. PMID: 30213523. doi:10.1016/j.eururo.2018.08.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。